IJCEP:乳腺癌淋巴结转移可预测

2014-11-23 MedSci原创 MedSci原创

研究背景:乳腺癌患者淋巴结转移与否与什么因素有关,这是一个广泛关注的问题,本研究拟讨论与淋巴结转移有关的因素,以便指导临床治疗。 研究方法:研究纳入2012-01~2013-12华山医院普外科收治的乳腺癌(原位癌除外)患者,纳入标准为:未远处转移、行乳腺肿瘤切除及淋巴结切除、原发肿瘤属于T1/T2期;整理其临床病理信息(初

研究背景:乳腺癌患者淋巴结转移与否与什么因素有关,这是一个广泛关注的问题,本研究拟讨论与淋巴结转移有关的因素,以便指导临床治疗。 研究方法:研究纳入2012-01~2013-12华山医院普外科收治的乳腺癌(原位癌除外)患者,纳入标准为:未远处转移、行乳腺肿瘤切除及淋巴结切除、原发肿瘤属于T1/T2期;整理其临床病理信息(初诊年龄、肿瘤大小、腋窝淋巴结状态、组织学类型、免疫组化结果),根据淋巴结有无转移分为两组,运用SAS软件进行统计学分析。研究结果:共纳入814名乳腺癌患者,其中42.1%有腋窝淋巴结转移,腋窝淋巴结转移与肿瘤大小有关(T1:36.6%、T2:54.9%  P<0.001)。此外,腋窝淋巴结阳性与否还与不同亚型有关,luminal Her2-亚型的患者有较高的腋窝淋巴结转移率(49.0%),其次是HER2+(44.4%),Luminal A (36.5%) 和 TNBC (34.7%),通过单变量/多变量逻辑回归模型分析结果显示:原发肿瘤较大、luminalB亚型与淋巴结转移显著相关。 研究结论:腋窝淋巴结转移与乳腺癌分子类型有关:在三阳性乳腺癌人群中转移较多

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1007657, encodeId=7282100e657aa, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Fri Aug 13 16:29:07 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062881, encodeId=6663206288184, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat May 09 22:04:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292953, encodeId=29b8129295391, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302493, encodeId=cceb130249380, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=)]
    2021-08-13 ms9000001748316827

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1007657, encodeId=7282100e657aa, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Fri Aug 13 16:29:07 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062881, encodeId=6663206288184, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat May 09 22:04:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292953, encodeId=29b8129295391, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302493, encodeId=cceb130249380, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=)]
    2015-05-09 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1007657, encodeId=7282100e657aa, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Fri Aug 13 16:29:07 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062881, encodeId=6663206288184, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat May 09 22:04:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292953, encodeId=29b8129295391, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302493, encodeId=cceb130249380, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=)]
    2014-11-25 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1007657, encodeId=7282100e657aa, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Fri Aug 13 16:29:07 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062881, encodeId=6663206288184, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat May 09 22:04:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292953, encodeId=29b8129295391, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302493, encodeId=cceb130249380, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Nov 25 11:04:00 CST 2014, time=2014-11-25, status=1, ipAttribution=)]

相关资讯

JAMA Surg:行保留乳房手术的乳腺癌患者越来越少?

JAMA Surg:行保留乳房手术的乳腺癌患者越来越少? 研究背景:早在19世纪80年代就有临床研究表,对于乳腺癌,保留乳房手术可以作为乳腺切除术的替代手术,1990年,美国国立卫生研究院批准对于早期乳腺癌患者使用保留乳房手术,之后保乳手术率稳定增加,然而有证据表明这种趋势在上个世纪末的10年开始下降。 研究目的:对于早期乳腺癌患者,行保乳手术率逐渐下降、乳房切除术率逐渐上升,本文拟分析造

BMC Cancer:术前贫血的乳腺癌患者有较差的预后

BMC Cancer:术前贫血的乳腺癌患者有较差的预后 研究背景:贫血是恶性肿瘤患者常见并发症,大量研究表明贫血肿瘤患者有较差预后, 41-82%乳腺癌患者伴有贫血,术前贫血的乳腺癌患者是否影响其预后有待研究。 研究目的:本研究拟讨论乳腺癌患者术前贫血是否影响其术后复发(局部复发、淋巴结转移、远处转移、总复发)和存活(无局部复发生存时间LRFS、无淋巴结转移生存时间LNMFS、无远处转移生

ESSO:乳腺癌保乳头乳房切除术评价

一项来自第34届欧洲肿瘤外科大会(ESSO)的最新研究显示,低风险和晚期乳腺癌患者可实施保留乳头的乳房切除术。该手术在肿瘤学上是安全的,通过同步即时重建获得了更好的美学结果。在晚期病例中,并发症的发生率与接受乳房切除术及后续放疗的患者所报告的相似。 保留乳头的乳房切除术(NSM)被作为乳腺癌外科治疗的手术之一。它包括乳房切除术同时保留覆盖乳房和乳头乳晕复合体的皮肤。采用组织扩张器即时重建,以获得

World J Surg Oncol:纤维腺瘤来源的乳腺癌(BcaFad)的研究

World J Surg Oncol:纤维腺瘤来源的乳腺癌(BcaFad)的研究 研究背景:纤维腺瘤是女性乳腺最常见肿瘤,良性无症状的纤维腺瘤可以不用手术,定期随访,然而纤维腺瘤可以转变成癌,尽管很罕见。因此临床特征和治疗原则尚不清,了解其临床病理特征和预后以及所经过的治疗方式进行分析,有望通过分析结果得到其特征和治疗上的启示,以便于指导治疗。 研究方法:通过PUBMED搜索1986年1月

EJSO:肿瘤整形手术在乳腺癌外科手术治疗的应用

来自塞尔维亚肿瘤学和放射学研究所的Djurisic等学者发表了关于肿瘤整形术在胸壁复发性叶状肿瘤治疗的应用的论文。该研究背景是肿瘤整形外科是肿瘤和整形外科的结合,遵守所有肿瘤学原则,同时为行乳腺癌手术女性患者提供满意的外观恢复。保留乳房术适用于最小的乳腺癌,完整切除肿块和周围腺体组织,同时保留乳房外观。保留乳房术与术后放疗常联合治疗。 研究视频中展示一位47岁女患者右乳腺癌保留乳腺术的技术,该患

Cell:Hedgehog信号通路为何引发乳腺癌转移?

长链非编码RNA(lncRNAs)与乳腺癌有牵连,但其在癌症转移和肿瘤生长中的相关机制仍不甚明朗。 得克萨斯大学MD安德森癌症中心科学家报告说,刺猬(hedgehog)是一个独特的细胞信号转导通路(其已知能导致许多类型的癌症),亦可能是乳腺癌转移的背后机制。这种分子与BCAR4协同,给肿瘤生长转移提供方便。 我们研究BCAR4和Hedgehog信号通路所得的研究结果提供了证据证实,即lnc